| |
Large-scale. Long-term. Maintenance studies in major depressive disorder are broad in scope, duration, and size. Build your optimal study plan and mitigate risk with the help of our guide. Learn more. .png)
|
|
Today’s Big NewsOct 8, 2024 |
|
These awards honor CROs that excel in innovation, quality, and leadership, highlighting their crucial role in advancing life sciences and improving patient outcomes. Enter now! 
|
|
| By Nick Paul Taylor The sun has set on Johnson & Johnson’s SunRISe-2 study. J&J called a halt to the phase 3 bladder cancer trial after an interim look at the data showed the TAR-200 candidate was no better than chemoradiation. |
|
|
|
By Nick Paul Taylor Sage Therapeutics has seen another clinical trial go up in smoke. The biotech called time on its plans to develop dalzanemdor in Alzheimer’s disease after seeing midphase data, adding to an earlier Parkinson’s flop and leaving the team looking to an upcoming readout in Huntington’s to rescue the prospect. |
By James Waldron Mestag has been working to change how fibroblasts are activated and how they expand. Now, Merck & Co. wants in—penning a $1.9 billion biobucks deal to collaborate on new therapies for inflammatory diseases. |
By Gabrielle Masson A new RNAi biotech is breaking ground with $135 million and John Maraganore, Ph.D., holding the key to the city. |
|
When the world is changing, you need a global CDMO with a strong global presence to protect your molecule. Our team of experts help progress any molecule type, however complex, from pre-clinical to commercial. Learn more about our tech transfer capabilities. 
|
|
By James Waldron Astellas has turned to AviadoBio to further boost its gene therapy pipeline, paying the British biotech $50 million in equity and upfront cash for a dementia candidate in phase 1. |
By James Waldron Black Diamond Therapeutics has deprioritized one of its two clinical-stage lung cancer contenders, jettisoned two executives and alluded to further layoffs in order to keep the money flowing to its lead candidate. |
By Fraiser Kansteiner Several months after forging a path forward for its Friedreich ataxia drug vatiquinone, PTC Therapeutics is back with some much-needed good news. PTC’s drug candidate passed muster by hitting pre-specified endpoints in two separate Friedreich ataxia (FA) long-term extension studies, the company said. |
By Angus Liu Merck & Co. hopes a new positive readout can return Keytruda to glory in head and neck cancer about two years after a prior failure. |
By Fraiser Kansteiner After winning a first-in-class nod for its two-drug inhaler Airsupra last January, AstraZeneca is bolstering the rescue treatment’s clinical package with new data showing it can cut the risk of asthma exacerbations regardless of patients’ disease severity. |
By Dave Muoio Facing a second major storm within two weeks, some hospitals on Florida's Gulf Coast are again closing up shop and transferring patients across the state. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote. |
|
|---|
|
|
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
Whitepaper Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner. Sponsored by: IQVIA |
Whitepaper When the fate of your company hangs in the balance, you need expert guidance to navigate the complexities of biotechnology development and to make informed decisions. Sponsored by: WCG |
Whitepaper Power non-invasive, self-sampling solutions using the Colli-Pee™️ first-void urine collection device. Learn more. Sponsored by: DNA Genotek |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
